With the addition of MYLOTARG, the probability of survival with no events occurring was more than double at 2 and 3 years vs chemotherapy alone1,2*
*Number of censored patients: 62 (46%) in the MYLOTARG + chemo arm, 34 (25%) in the chemotherapy arm.
EFS was a clinically meaningful endpoint in the Phase 3, open-label study
- MYLOTARG is the first drug approved by the FDA based on EFS as a primary endpoint, defined as the time from randomization to induction failure, relapse, or death1
- EFS is an indirect measure of durable remission3